Previous Close | 67.47 |
Open | 66.53 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 900 |
Day's Range | 64.76 - 66.84 |
52 Week Range | 60.76 - 120.54 |
Volume | |
Avg. Volume | 2,455,046 |
Market Cap | 14.721B |
Beta (5Y Monthly) | 1.16 |
PE Ratio (TTM) | 27.57 |
EPS (TTM) | 2.35 |
Earnings Date | Feb 23, 2022 - Mar 02, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 137.50 |
Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged.
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
One thing we could say about the analysts on Horizon Therapeutics Public Limited Company ( NASDAQ:HZNP ) - they aren't...